Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306254985> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4306254985 abstract "Abstract Background Doxorubicin-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in breast cancer patients. Sacubitril-valsartan (LCZ 696) is a combination drug, made up of neprilysin inhibitor sacubitril and angiotensin II receptor blocker valsartan, used for the treatment of heart failure in patients with a reduced ejection fraction. Purpose We hypothesized that LCZ 696, administered during doxorubicin, could improve cardiac function Methods Female C57Bl/6 mice were untreated (Sham, n=6) or treated for 10 days with doxorubicin i.p at 2.17 mg/kg (DOXO, n=6), LCZ-696 at 60 mg/kg (LCZ, n=6) or doxorubicin combined to LCZ-696 (DOXO-LCZ, n=6). Ejection fraction, radial and longitudinal strain were analyzed through transthoracic echocardiography (Vevo 2100). Cardiac tissue expression of NLRP3 inflammasome, Myd88, DAMPs (galectine 3 and calgranulinS100), pAMPK, NF-kB, and 13 chemokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL17-α, IL-18, IFN-γ, TNF-α, G-CSF, and GM-CSF) were quantified through ELISA and western blot methods. Results LCZ 696 improved significantly the EF and prevented the reduction of radial and longitudinal strain after 10 days of treatment with doxorubicin. A reduced expression of NLRP3, MyD88, DAMPs and NF-kB in cardiac tissues was seen in DOXO-LCZ group compared to DOXO mice (p<0.001). Cardiac expression of IL-1β, IL-6, TNF-α, G-CSF and GM-CSF were significantly reduced after treatment with LCZ-696 indicating anti-inflammatory properties. Expression of pAMPK was strongly enhanced in LCZ-696-DOXO compared to DOXO group. Levels of Calgranulin S100 and galectine-3 were strongly enhanced in DOXO group; on the other hand their expression were reduced by 47.7 and 52.3% in LCZ-696-DOXO group vs DOXO (p<0.005). Conclusion In this preclinical study, LCZ-696 is able to improve cardiac function and reduce biomarkers involved in heart failure and fibrosis. The overall picture of the study pushes the use of Sacubitril-valsartan in prevention of cardiomyopathies induced by anthracyclines in cancer patients. Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): Ricerca Corrente, Ministero della Salute" @default.
- W4306254985 created "2022-10-15" @default.
- W4306254985 creator A5006722565 @default.
- W4306254985 creator A5045173249 @default.
- W4306254985 creator A5053079506 @default.
- W4306254985 creator A5060912538 @default.
- W4306254985 creator A5064994916 @default.
- W4306254985 creator A5066774199 @default.
- W4306254985 creator A5069310507 @default.
- W4306254985 creator A5075134017 @default.
- W4306254985 creator A5083264214 @default.
- W4306254985 date "2022-10-01" @default.
- W4306254985 modified "2023-10-06" @default.
- W4306254985 title "Sacubitril-valsartan activates pAMPK and reduces NLRP3, MyD88, cytokines/growth factors and DAMPs in doxorubicin-treated mice improving longitudinal strain and ejection fraction" @default.
- W4306254985 doi "https://doi.org/10.1093/eurheartj/ehac544.2727" @default.
- W4306254985 hasPublicationYear "2022" @default.
- W4306254985 type Work @default.
- W4306254985 citedByCount "0" @default.
- W4306254985 crossrefType "journal-article" @default.
- W4306254985 hasAuthorship W4306254985A5006722565 @default.
- W4306254985 hasAuthorship W4306254985A5045173249 @default.
- W4306254985 hasAuthorship W4306254985A5053079506 @default.
- W4306254985 hasAuthorship W4306254985A5060912538 @default.
- W4306254985 hasAuthorship W4306254985A5064994916 @default.
- W4306254985 hasAuthorship W4306254985A5066774199 @default.
- W4306254985 hasAuthorship W4306254985A5069310507 @default.
- W4306254985 hasAuthorship W4306254985A5075134017 @default.
- W4306254985 hasAuthorship W4306254985A5083264214 @default.
- W4306254985 hasBestOaLocation W43062549851 @default.
- W4306254985 hasConcept C111566952 @default.
- W4306254985 hasConcept C126322002 @default.
- W4306254985 hasConcept C134018914 @default.
- W4306254985 hasConcept C164705383 @default.
- W4306254985 hasConcept C2776694085 @default.
- W4306254985 hasConcept C2776754050 @default.
- W4306254985 hasConcept C2777387769 @default.
- W4306254985 hasConcept C2778198053 @default.
- W4306254985 hasConcept C2781303535 @default.
- W4306254985 hasConcept C71924100 @default.
- W4306254985 hasConcept C78085059 @default.
- W4306254985 hasConcept C84393581 @default.
- W4306254985 hasConcept C98274493 @default.
- W4306254985 hasConceptScore W4306254985C111566952 @default.
- W4306254985 hasConceptScore W4306254985C126322002 @default.
- W4306254985 hasConceptScore W4306254985C134018914 @default.
- W4306254985 hasConceptScore W4306254985C164705383 @default.
- W4306254985 hasConceptScore W4306254985C2776694085 @default.
- W4306254985 hasConceptScore W4306254985C2776754050 @default.
- W4306254985 hasConceptScore W4306254985C2777387769 @default.
- W4306254985 hasConceptScore W4306254985C2778198053 @default.
- W4306254985 hasConceptScore W4306254985C2781303535 @default.
- W4306254985 hasConceptScore W4306254985C71924100 @default.
- W4306254985 hasConceptScore W4306254985C78085059 @default.
- W4306254985 hasConceptScore W4306254985C84393581 @default.
- W4306254985 hasConceptScore W4306254985C98274493 @default.
- W4306254985 hasIssue "Supplement_2" @default.
- W4306254985 hasLocation W43062549851 @default.
- W4306254985 hasOpenAccess W4306254985 @default.
- W4306254985 hasPrimaryLocation W43062549851 @default.
- W4306254985 hasRelatedWork W2357609130 @default.
- W4306254985 hasRelatedWork W2385466232 @default.
- W4306254985 hasRelatedWork W2622922034 @default.
- W4306254985 hasRelatedWork W2624092862 @default.
- W4306254985 hasRelatedWork W2948540269 @default.
- W4306254985 hasRelatedWork W2979410390 @default.
- W4306254985 hasRelatedWork W2987185485 @default.
- W4306254985 hasRelatedWork W4224986348 @default.
- W4306254985 hasRelatedWork W4289711873 @default.
- W4306254985 hasRelatedWork W4297539405 @default.
- W4306254985 hasVolume "43" @default.
- W4306254985 isParatext "false" @default.
- W4306254985 isRetracted "false" @default.
- W4306254985 workType "article" @default.